Retrospective data analysis of the history of patients treated for malignant melanoma at the Department of Dermatology, Jagiellonian University between 1991 and 2008

Postepy Dermatologii i Alergologii

Volumn 28, Issue 2, 2011, Pages 92-96

  Czerwińska, Magdalena ^a   Alekseenko, Ana ^a   Rup, Elzbieta ^a   Lipko Godlewska, Sylwia ^a   Fastnacht, Agnieszka ^a   Wojas Pelc, Anna ^a   Ogiela, Jakub ^b   Chlebicki, Michał ^b  

^a JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^b JAGIELLONIAN UNIVERSITY   (Poland)

Author keywords

Breslow scale; Lentigo maligna; Melanoma

Indexed keywords

ACRAL LENTIGINOUS MELANOMA; ADULT; ADVANCED CANCER; AGE; ARM; ARTICLE; CANCER CLASSIFICATION; CANCER EPIDEMIOLOGY; CANCER INCIDENCE; CANCER LOCALIZATION; CANCER PATIENT; CANCER SIZE; CANCER SURGERY; DISEASE SEVERITY; FACE; FEMALE; FOOT; GENDER; HAND; HEAD AND NECK CANCER; HISTOPATHOLOGY; HUMAN; LEG; MAJOR CLINICAL STUDY; MALE; MALIGNANT LENTIGO; MEDICAL HISTORY; MELANOMA; MORBIDITY; NEVUS; RETROSPECTIVE STUDY; SKIN CANCER; SUN EXPOSURE; TRUNK;

EID: 79955612092     PISSN: 1642395X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (39)

1. Didkowska J, Wojciechowska U, Tarkowski W, et al. Nowotwory złośliwe w Polsce w 2005 roku. Centrum Onkologii - Instytut im. M. Skłodowskiej-Curie, Warszawa 2007.
2. Berwick M, Wiggins C. The current epidemiology of cutaneous malignant melanoma. Frontiers in Bioscience 2006; 11: 1244-54. (Pubitemid 43253416)
3. Marks R. An overview of skin cancers: incidence and causation. Cancer 1995; 75: 607-12.
4. de Vries E, Coebergh JW. Cutaneous malignant melanoma in Europe. Eur J Cancer 2004; 40: 2355-66.
5. Armstrong BK, Kricker A. Cutaneous melanoma. Cancer Surv 1994; 19-20: 219-40. (Pubitemid 24289387)
6. Chang AE, Karnell LH, Menck HR. American College of Surgeons Commission on Cancer, American Cancer Society. The National Cancer Data Base report on cutaneous and noncutaneous melanoma: a summary of 84,836 cases from the past decade. Cancer 1998; 83: 1664-78. (Pubitemid 28465486)
7. Cummins DL,Cummins JM, Pantle H, et al. Cutaneous malignant melanoma. Mayo Clin Proc 2006; 81: 500-7.
8. Marks R. Epidemiology of melanoma. Clin Exp Dermatol 2000; 25: 459-63.
9. Richard MA, Grob JJ, Avril MF, et al. Melanoma and tumor thickness. Challenges of early diagnosis. Arch Dermatol 1999; 135: 269-74.
10. Donald L, Morton MD, David G, et al. Multivariate analysis of the relationship between survival and the microstage of primary melanoma by Clark level and Breslow thickness. Cancer 1993; 71: 3737-43.
11. Ruka W, Krzakowski M, Placek W, et al. Czerniaki skóry - zasady postȩpowania diagnostyczno-terapeutycznego. Przegl Dermatol 2009; 96: 193-203.
12. Wojas-Pelc A, Rajzer L, Jaworek A, Woźniak W. Najnowsze metody diagnostyczne i leczenie w czerniaku. A New diagnostic methods and treatment of the melanoma. Przegl Lek 2006; 63: 674-80.
13. Elwood JM, Jopson J. Melanoma and sun exposure: an overview of published studies. Int J Ca 1997; 73: 198-203. (Pubitemid 27448818)
14. Brudnik U, Wojas-Pelc A, Branicki W. Genetyczne uwarunkowania czerniaka. Post Dermatol Alergol 2006; XXIII: 21-5.
15. Kawaoka JC, Weinstock MA. Melanoma: a current overview. Med Health R I 2004; 87: 128-31.
16. Newnham A, Moller H. Trends in the incidence of cutaneous malignant melanomas in the south east of England, 1960- 1998. J Public Health Med 2002; 24: 268-75.
17. de Vries E, Nijsten TE, Visser O, et al. Superior survival of females among 10,538 Dutch melanoma patients is independent of Breslow thickness, histologic type and tumor site. Ann Oncol 2008; 19: 583-9. (Pubitemid 351325683)
18. Clark LN, Shin DB, Troxel AB, et al. Association between the anatomic distribution of melanoma and sex. J Am Acad Dermatol 2007; 56: 768-73. (Pubitemid 46561015)
19. Garbe C, McLeod GR, Buettner PG. Time trends of cutaneous melanoma in Queensland, Australia and Central Europe. Cancer 2000; 89: 1269-78.
20. Kycler W, Grodecka-Gazdecka S, Teresiak M, et al. Wpływ wybranych cech klinicznych i morfologicznych na czas przeżycia chorych na czerniaka skóry. Współcz Onkol 2001; 5: 52-7.
21. Purdue MP, From L, Armstrong BK, et al. Etiologic and other factors predicting nevus-associated cutaneous malignant melanoma. Cancer Epidemiol Biomarkers Prev 2005; 14: 2015-22. (Pubitemid 41161217)
22. Kelly JW, Yeatman JM, Regalia C, et al. A high incidence of melanoma found in patients with multiple dysplastic naevi using photographic surveillance. Med J Australia 1997; 167: 191-4. (Pubitemid 27387245)
23. Marks R, Dorevitch AP, Mason G. Do all melanomas come from "moles"? A study of the histological association between melanocytic naevi and melanoma. Australas J Dermatol 1990; 31: 77-80.
24. Bevona C, Goggins W, Quinn T, et al. Cutaneous melanomas associated with nevi. Arch Dermatol 2003; 139: 1620-4. (Pubitemid 37523082)
25. Urso C, Giannotti V, Reali UM, et al. Spatial association of melanocytic naevus and melanoma. Melanoma Res 1991; 1: 245-9.
26. Skender-Kalnenas TM, English DR, Heenan PJ. Benign melanocytic lesions: risk markers or precursors of cutaneous melanoma? J Am Acad Dermatol 1995; 33: 1000-7.
27. Cohen LM. Lentigo maligna and lentigo maligna melanoma. J Am Acad Dermatol 1995; 33: 923-36.
28. Rivers JK. Is there more than one road to melanoma? Lancet 2004; 363: 728-30.
29. Cox NH, Aitchison TC, Sirel JM, et al. Comparison between lentigo maligna melanoma and other histogenetic types of malignant melanoma of the head and neck. Br J Cancer 1996; 73: 940-4. (Pubitemid 26110168)
30. Psaty EL, Scope A, Halpern AC, et al. Defining the patients risk for melanoma. Int J Dermatol 2010; 49: 362-76.
31. Nagore E, Hueso L, Otella-Estrada R, et al. Smoking, sun-exposure, number of nevi and previous neoplasias are risk factors for melanoma in older patients (60 years and older). JEADV 2010; 24: 50-7.
32. Gerbaud L, Lejeune ML, Abou-Samra T, et al. Epidemiological survey of melanoma in the Auvergne region (France): is there an increased incidence in Auvergne? Eur J Epidemiol 2003; 18: 331-5.
33. Scoggins CR, Ross MI, Reintgen DS, et al. Gender-related differences in outcome for melanoma patients. Ann Surg 2006; 243: 693-700.
34. Bailin PL, Meine JS, Poblete-Lopez C. Management of primary melanoma. In: Melanoma: biologically targeted therapeutics. Borden EC (ed). Humana Press, Totowa, New Jersey 2002; 3-39.
35. Markovic SN, Erickson LA, Rao RD, et al. Malignant melanoma in the 21st Century. Part 1: epidemiology, risk factors, screening, prevention, and diagnosis. Mayo Clin Proc 2007; 82: 364-80.
36. Bradford PT, Goldstein AM, McMaster ML, et al. Acral lentiginous melanoma: incidence and survival patterns in the United States, 1986-2005. Arch Dermatol 2009; 145: 427-34.
37. Kycler W, Teresiak M. Retrospektywna ocena czynników ryzyka u pacjentów z czerniakiem skóry po regionalnej limfadenektomii oraz pacjentów jedynie po miejscowym wyciȩciu guza. Post Dermatol Alergol 2007; 24: 26-34. (Pubitemid 46605121)
38. Kelly JW, Chamberlain AJ, Staples MP, et al. Nodular melanoma. No longer as simple as ABC. Australian Family Physician 2003; 32: 706-9.
39. Brudnik U, Wojas-Pelc A. Profilaktyka czerniaka w przypadku wystȩpowania znamion atypowych. Dermatol Est 2004; 4: 207-10.